XKRX
065660
Market cap120mUSD
Oct 08, Last price
16,190.00KRW
1D
-0.12%
1Q
-17.10%
Jan 2017
-31.69%
IPO
-58.17%
Name
Anterogen Co Ltd
Chart & performance
P/E
—
P/S
21.50
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.03%
Rev. gr., 5y
12.67%
Revenues
7.54b
+8.71%
Net income
-1.09b
L-52.27%
CFO
-1.02b
L+18.52%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Anterogen.Co.,Ltd., a South Korean bio-venture founded in 2000 and headquartered in Seoul, specializes in the global research, development, and commercialization of therapeutic products utilizing adipose-derived stem cells. Their pharmaceutical offerings include Cupistem injection, an adipose stem cell product for treating Crohn's fistula; Queencell, a stromal vascular fraction aimed at regenerating subcutaneous adipose tissue; and Remodulin injection, which addresses pulmonary arterial hypertension. The company also produces a line of cosmetics, featuring SCM2 and SCM2-Black for hair care, and Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione for skin care, along with providing human stem cell conditioned media as a cosmetic raw material. Furthermore, Anterogen offers services such as cell banking and various analytical services, including sample analysis for clinical studies and biopharmaceutical testing for identification, purity, potency, and adventitious viruses.
Key people
Sun Bae Kim
Internal Auditor
Won Dae Kim
Internal Auditor · since 2022
Hong Gi Ryu
Internal Auditor · since 2023
Managing Director
Mi Hyeong Kim
Co-Chief Executive Officer, Vice President, Director · since 2022
Seong Gu Lee
Co-Chief Executive Officer, Director · since 2022
Tae Hui Lee
Managing Director · since 2023
Min Jeong Gwak
Non-Executive Independent Director · since 2025
Chi Jung Kim
Non-Executive Independent Director
Non-Executive Independent Director
Gyeong Lee
Non-Executive Independent Director · since 2023
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||